Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema

Kaori Tenkumo, Kouki Fukuda, Ayana Yamashita, Chieko Shiragami, Hidetaka Yamaji, Fumio Shiraga

Research output: Contribution to journalArticle

Abstract

To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion (BRVO) with macular edema. Cases and Method : This study was made on 33 eyes of 33 patients who received intravitreal bevacizumab for BRVO with macular edema. The age ranged from 44 to 78 years, average 63 years. Cases were followed up for 8 to 49 months, average 15 months, after treatment. Visual acuity was evaluated in terms of logMAR. Results : Visual acuity averaged 0.47 before treatment and 0.23 at the last visit. The difference was significant (p

Original languageEnglish
Pages (from-to)877-880
Number of pages4
JournalJapanese Journal of Clinical Ophthalmology
Volume64
Issue number6
Publication statusPublished - Jun 2010
Externally publishedYes

Fingerprint

Retinal Vein Occlusion
Macular Edema
Visual Acuity
Intravitreal Injections
Therapeutics
Bevacizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema. / Tenkumo, Kaori; Fukuda, Kouki; Yamashita, Ayana; Shiragami, Chieko; Yamaji, Hidetaka; Shiraga, Fumio.

In: Japanese Journal of Clinical Ophthalmology, Vol. 64, No. 6, 06.2010, p. 877-880.

Research output: Contribution to journalArticle

Tenkumo, Kaori ; Fukuda, Kouki ; Yamashita, Ayana ; Shiragami, Chieko ; Yamaji, Hidetaka ; Shiraga, Fumio. / Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema. In: Japanese Journal of Clinical Ophthalmology. 2010 ; Vol. 64, No. 6. pp. 877-880.
@article{45d9d5adde6e4ceaa71d12cee5e3c4ef,
title = "Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema",
abstract = "To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion (BRVO) with macular edema. Cases and Method : This study was made on 33 eyes of 33 patients who received intravitreal bevacizumab for BRVO with macular edema. The age ranged from 44 to 78 years, average 63 years. Cases were followed up for 8 to 49 months, average 15 months, after treatment. Visual acuity was evaluated in terms of logMAR. Results : Visual acuity averaged 0.47 before treatment and 0.23 at the last visit. The difference was significant (p",
author = "Kaori Tenkumo and Kouki Fukuda and Ayana Yamashita and Chieko Shiragami and Hidetaka Yamaji and Fumio Shiraga",
year = "2010",
month = "6",
language = "English",
volume = "64",
pages = "877--880",
journal = "Japanese Journal of Clinical Ophthalmology",
issn = "0370-5579",
publisher = "Igaku-Shoin Ltd",
number = "6",

}

TY - JOUR

T1 - Mid-term outcome of intravitreal bevacizumab for branch retinal vein occlusion with macular edema

AU - Tenkumo, Kaori

AU - Fukuda, Kouki

AU - Yamashita, Ayana

AU - Shiragami, Chieko

AU - Yamaji, Hidetaka

AU - Shiraga, Fumio

PY - 2010/6

Y1 - 2010/6

N2 - To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion (BRVO) with macular edema. Cases and Method : This study was made on 33 eyes of 33 patients who received intravitreal bevacizumab for BRVO with macular edema. The age ranged from 44 to 78 years, average 63 years. Cases were followed up for 8 to 49 months, average 15 months, after treatment. Visual acuity was evaluated in terms of logMAR. Results : Visual acuity averaged 0.47 before treatment and 0.23 at the last visit. The difference was significant (p

AB - To report the outcome of intravitreal injection of bevacizumab for branch retinal vein occlusion (BRVO) with macular edema. Cases and Method : This study was made on 33 eyes of 33 patients who received intravitreal bevacizumab for BRVO with macular edema. The age ranged from 44 to 78 years, average 63 years. Cases were followed up for 8 to 49 months, average 15 months, after treatment. Visual acuity was evaluated in terms of logMAR. Results : Visual acuity averaged 0.47 before treatment and 0.23 at the last visit. The difference was significant (p

UR - http://www.scopus.com/inward/record.url?scp=77954343765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954343765&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77954343765

VL - 64

SP - 877

EP - 880

JO - Japanese Journal of Clinical Ophthalmology

JF - Japanese Journal of Clinical Ophthalmology

SN - 0370-5579

IS - 6

ER -